SBH
BMY.RT

Segall Bryant & Hamill’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Segall Bryant & Hamill’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,141
Closed -$23K – 764
2020
Q3 		$23K Buy
10,141
+27
+0.3% +$77 ﹤0.01% 705
2020
Q2 		$36K Sell
10,114
-7,330
-42% -$26.4K ﹤0.01% 771
2020
Q1 		$66K Hold
17,444
– – ﹤0.01% 769
2019
Q4 		$51K Buy
+17,444
New +$45.4K ﹤0.01% 811

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFS
Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return
LGP
Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Segall Bryant & Hamill's BMY.RT Position: Q4 2020 in Review

Segall Bryant & Hamill sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 10,141 shares — an estimated $23K sold.

Segall Bryant & Hamill first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $66K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Segall Bryant & Hamill reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Segall Bryant & Hamill sold 10,141 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $23K.
  • Segall Bryant & Hamill first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Segall Bryant & Hamill's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $66K in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Segall Bryant & Hamill's 13F filing for Q4 2020, filed 12 Feb 2021.